JP2001524809A5 - - Google Patents

Download PDF

Info

Publication number
JP2001524809A5
JP2001524809A5 JP1998527507A JP52750798A JP2001524809A5 JP 2001524809 A5 JP2001524809 A5 JP 2001524809A5 JP 1998527507 A JP1998527507 A JP 1998527507A JP 52750798 A JP52750798 A JP 52750798A JP 2001524809 A5 JP2001524809 A5 JP 2001524809A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP1998527507A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001524809A (ja
Filing date
Publication date
Priority claimed from US08/766,975 external-priority patent/US6022683A/en
Application filed filed Critical
Publication of JP2001524809A publication Critical patent/JP2001524809A/ja
Publication of JP2001524809A5 publication Critical patent/JP2001524809A5/ja
Withdrawn legal-status Critical Current

Links

JP52750798A 1996-12-16 1997-12-16 神経系疾患の治療に使用するための遺伝薬理学的方法 Withdrawn JP2001524809A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/766,975 1996-12-16
US08/766,975 US6022683A (en) 1996-12-16 1996-12-16 Methods for assessing the prognosis of a patient with a neurodegenerative disease
PCT/IB1997/001648 WO1998027227A2 (en) 1996-12-16 1997-12-16 Pharmacogenetic methods for use in the treatment of nervous system diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009113073A Division JP5202429B2 (ja) 1996-12-16 2009-05-07 神経系疾患の治療に使用するための遺伝薬理学的方法

Publications (2)

Publication Number Publication Date
JP2001524809A JP2001524809A (ja) 2001-12-04
JP2001524809A5 true JP2001524809A5 (cg-RX-API-DMAC10.html) 2005-08-11

Family

ID=25078098

Family Applications (4)

Application Number Title Priority Date Filing Date
JP52750798A Withdrawn JP2001524809A (ja) 1996-12-16 1997-12-16 神経系疾患の治療に使用するための遺伝薬理学的方法
JP2009113073A Expired - Fee Related JP5202429B2 (ja) 1996-12-16 2009-05-07 神経系疾患の治療に使用するための遺伝薬理学的方法
JP2012117411A Pending JP2012152229A (ja) 1996-12-16 2012-05-23 神経系疾患の治療に使用するための遺伝薬理学的方法
JP2012274378A Pending JP2013059347A (ja) 1996-12-16 2012-12-17 神経系疾患の治療に使用するための遺伝薬理学的方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2009113073A Expired - Fee Related JP5202429B2 (ja) 1996-12-16 2009-05-07 神経系疾患の治療に使用するための遺伝薬理学的方法
JP2012117411A Pending JP2012152229A (ja) 1996-12-16 2012-05-23 神経系疾患の治療に使用するための遺伝薬理学的方法
JP2012274378A Pending JP2013059347A (ja) 1996-12-16 2012-12-17 神経系疾患の治療に使用するための遺伝薬理学的方法

Country Status (8)

Country Link
US (2) US6022683A (cg-RX-API-DMAC10.html)
EP (2) EP0946753B1 (cg-RX-API-DMAC10.html)
JP (4) JP2001524809A (cg-RX-API-DMAC10.html)
AT (1) ATE269978T1 (cg-RX-API-DMAC10.html)
AU (2) AU5571798A (cg-RX-API-DMAC10.html)
CA (2) CA2275504C (cg-RX-API-DMAC10.html)
DE (2) DE69729473T2 (cg-RX-API-DMAC10.html)
WO (2) WO1998027226A2 (cg-RX-API-DMAC10.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022683A (en) * 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease
US6218117B1 (en) 1998-06-15 2001-04-17 Mitokor Compositions and methods for identifying agents that quantitatively alter detectable extramitochondrial DNA:mitochondrial DNA ratios
US6441149B1 (en) 1998-06-15 2002-08-27 Mitokor Diagnostic method based on quantification of extramitochondrial DNA
US6489095B2 (en) 1998-06-15 2002-12-03 Mitokor Diagnostic method based on quantification of extramitochondrial DNA
DE69929787T2 (de) 1998-06-16 2006-11-09 Poirier, Judes Verfahren zur behandlung von neurologischen erkrankungen mit hilfe der bestimmung des bche genotyps
EP1117840A1 (en) 1998-10-01 2001-07-25 Variagenics, Inc. Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant gpiiia and/or variant gpiib allele
WO2000070340A2 (en) * 1999-05-14 2000-11-23 Karolinska Innovations Ab Materials and methods relating to disease diagnosis
US7058517B1 (en) 1999-06-25 2006-06-06 Genaissance Pharmaceuticals, Inc. Methods for obtaining and using haplotype data
DE1233366T1 (de) * 1999-06-25 2003-03-20 Genaissance Pharmaceuticals Inc., New Haven Verfahren zur herstellung und verwendung von Haplotype Daten
US6960439B2 (en) * 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6692916B2 (en) * 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6573049B1 (en) 1999-07-26 2003-06-03 Nuvelo, Inc. Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease
US6896881B1 (en) 1999-09-24 2005-05-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
WO2001069261A2 (en) * 2000-03-15 2001-09-20 Oxford Glycosciences (Uk) Ltd. Proteins, genes and their use for diagnosis and treatment of vascular dementia
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US20070179197A1 (en) * 2000-05-01 2007-08-02 Accera, Inc. Compositions and methods for improving or preserving brain function
US20020006959A1 (en) 2000-05-01 2002-01-17 Henderson Samuel T. Use of medium chain triglycerides for the treatment and prevention of Alzheimer's Disease and other diseases resulting from reduced Neuronal Metabolism
US20080009467A1 (en) * 2000-05-01 2008-01-10 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism
US6931326B1 (en) 2000-06-26 2005-08-16 Genaissance Pharmaceuticals, Inc. Methods for obtaining and using haplotype data
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
AU2002237847A1 (en) * 2001-02-12 2002-08-28 Akzo Nobel N.V Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4
GB0106051D0 (en) * 2001-03-12 2001-05-02 Isis Innovation Diagnostic screens for alzheimer's disease
US20030104453A1 (en) * 2001-11-06 2003-06-05 David Pickar System for pharmacogenetics of adverse drug events
CN1612936A (zh) * 2001-11-09 2005-05-04 苏尔斯精细医药公司 利用基因表达分布图识别、监控和治疗疾病以及鉴定生物学状态
US20030224446A1 (en) * 2001-12-20 2003-12-04 Harry G. Jean Method of predicting cytokine response to tissue injury
US20040267458A1 (en) * 2001-12-21 2004-12-30 Judson Richard S. Methods for obtaining and using haplotype data
WO2003069431A2 (en) * 2002-02-14 2003-08-21 Medavante, Inc. System and method for facilitating candidate and subject participation in clinical trial studies
US7432355B2 (en) * 2002-08-09 2008-10-07 The J. David Gladstone Institutes Apolipoprotein E stable folding intermediate and methods of use thereof
US8688385B2 (en) 2003-02-20 2014-04-01 Mayo Foundation For Medical Education And Research Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
EP1636592B1 (en) * 2003-06-19 2012-12-19 Merck Serono SA Use of prion conversion modulating agents
US20050038692A1 (en) * 2003-08-14 2005-02-17 Kane John Michael System and method for facilitating centralized candidate selection and monitoring subject participation in clinical trial studies
WO2005073892A2 (en) * 2004-01-16 2005-08-11 Disease Management Services, Plc Disease management system
CA2573673A1 (en) 2004-07-16 2006-01-26 Proteosys Ag Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents
US20060252775A1 (en) * 2005-05-03 2006-11-09 Henderson Samuel T Methods for reducing levels of disease associated proteins
US20070135376A1 (en) * 2005-06-20 2007-06-14 Accera, Inc. Method to reduce oxidative damage and improve mitochondrial efficiency
EP3703058A1 (en) * 2005-11-29 2020-09-02 Children's Hospital Medical Center A method of selecting a medication for a patient
KR101634083B1 (ko) * 2006-04-03 2016-06-28 액세라인크 나이와 관련된 기억 손상의 치료를 위한 케톤 생성 조성물의 용도
US20080126118A1 (en) * 2006-11-24 2008-05-29 General Electric Company, A New York Corporation Systems, methods and apparatus for a network application framework system
TWI362012B (en) * 2007-07-23 2012-04-11 System of providing hygienic education information and method thereof
KR101335021B1 (ko) 2007-07-31 2013-12-12 액세라인크 게놈 테스트의 용도 및 인지 기능 저하 치료용 케톤성 화합물
US20090198504A1 (en) * 2008-02-05 2009-08-06 Medavante, Inc. Rater resource allocation systems and methods
US8105809B2 (en) * 2008-07-03 2012-01-31 Accera, Inc. Enzymatic synthesis of acetoacetate esters and derivatives
AU2009266869B2 (en) * 2008-07-03 2016-07-07 Cerecin Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
EP2379080A1 (en) 2009-01-13 2011-10-26 ProteoSys AG Pirenzepine as otoprotective agent
EP2360280A1 (en) * 2010-02-24 2011-08-24 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Genetic marker for the diagnosis of dementia with Lewy bodies
US20120078521A1 (en) * 2010-09-27 2012-03-29 General Electric Company Apparatus, system and methods for assessing drug efficacy using holistic analysis and visualization of pharmacological data
US20130080182A1 (en) * 2011-09-26 2013-03-28 Athleticode Inc. Methods For Using DNA Testing To Screen For Genotypes Relevant To Athleticism, Health And Risk Of Injury
RU2467680C1 (ru) * 2011-10-04 2012-11-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации Способ прогнозирования эффективности лечения больных ишемическим инсультом
US10665328B2 (en) 2014-06-30 2020-05-26 QIAGEN Redwood City, Inc. Methods and systems for interpretation and reporting of sequence-based genetic tests
US10658073B2 (en) 2014-08-15 2020-05-19 QIAGEN Redwood City, Inc. Methods and systems for interpretation and reporting of sequence-based genetic tests using pooled allele statistics
EP3628315A1 (en) 2018-09-28 2020-04-01 Université de Caen Normandie Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases
WO2020091375A2 (ko) * 2018-10-29 2020-05-07 고려대학교 산학협력단 항우울제 추천 방법 및 시스템

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE625212T1 (de) * 1992-10-13 2000-11-02 Duke University, Durham Verfahren zum entdecken von krankheit von alzheimer.
CA2111503A1 (en) * 1993-12-15 1995-06-16 Mcgill University Apolipoprotein e polymorphism and alzheimer's disease
FR2716894B1 (fr) * 1994-03-07 1996-05-24 Pasteur Institut Marqueurs génétiques utilisés conjointement pour le diagnostic de la maladie d'Alzheimer, méthode et kit de diagnostic.
GB9408465D0 (en) * 1994-04-27 1994-06-22 Univ Mcgill Apolipoprotein e polymorphism & treatment of alzheimer's disease
GB9415073D0 (en) * 1994-06-27 1994-09-14 Smithkline Beecham Plc Novel method
GB9414624D0 (en) * 1994-07-20 1994-09-07 Smithkline Beecham Plc Novel method
US6022683A (en) * 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease

Similar Documents

Publication Publication Date Title
JP2000502280A5 (cg-RX-API-DMAC10.html)
JP2000501771A5 (cg-RX-API-DMAC10.html)
JP2000501599A5 (cg-RX-API-DMAC10.html)
JP2000500076A5 (cg-RX-API-DMAC10.html)
JP2000503342A5 (cg-RX-API-DMAC10.html)
JP2000500055A5 (cg-RX-API-DMAC10.html)
JP2000500026A5 (cg-RX-API-DMAC10.html)
JP2000502472A5 (cg-RX-API-DMAC10.html)
JP2000501825A5 (cg-RX-API-DMAC10.html)
JP2000500874A5 (cg-RX-API-DMAC10.html)
JP2001524809A5 (cg-RX-API-DMAC10.html)
JP2001502229A5 (cg-RX-API-DMAC10.html)
JP2000502485A5 (cg-RX-API-DMAC10.html)
JP2000502425A5 (cg-RX-API-DMAC10.html)
JP2000502568A5 (cg-RX-API-DMAC10.html)
JP2000501774A5 (cg-RX-API-DMAC10.html)
JP2000516080A5 (cg-RX-API-DMAC10.html)
JP2000500912A5 (cg-RX-API-DMAC10.html)
JP2001505816A5 (cg-RX-API-DMAC10.html)
JP2000502570A5 (cg-RX-API-DMAC10.html)
JP2000501876A5 (cg-RX-API-DMAC10.html)
JP2000501744A5 (cg-RX-API-DMAC10.html)
JP2000500857A5 (cg-RX-API-DMAC10.html)
JP2000502316A5 (cg-RX-API-DMAC10.html)
JP2000502714A5 (cg-RX-API-DMAC10.html)